James Choi
Internal Medicine · Lansing, MINPI 1063907947
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,470 of the $7,447 with a category attached, or 60.0%. 35 manufacturers reported payments, led by Intuitive Surgical at 40.4% of the total. 2025 is the largest year on record at $4,141, more than ten times the $46 reported in 2019. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $32.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$1K
- Boehringer Ingelheim$630
- GSK$444
- Grifols USA, LLC$257
- Regeneron Healthcare Solutions, Inc.$233
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2153%
- Food & beverage$4,47060%
- Education$2,76337%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $3,005 |
| AstraZeneca | 63 | $1,215 |
| Boehringer Ingelheim | 29 | $630 |
| GSK | 28 | $444 |
| Grifols USA, LLC | 14 | $257 |
| Regeneron Healthcare Solutions, Inc. | 12 | $233 |
| Mylan Specialty L.p. | 9 | $202 |
| Sanofi-aventis U.S. LLC | 2 | $183 |
| Jazz Pharmaceuticals Inc. | 4 | $121 |
| Insmed, Inc. | 6 | $116 |
| Bayer | 6 | $114 |
| Sanofi | 4 | $86 |
| Verona Pharma, Inc. | 4 | $83 |
| Actelion Pharmaceuticals US, Inc. | 1 | $80 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $60 |
| Viatris Specialty LLC | 3 | $58 |
| Pfizer | 4 | $58 |
| Merck | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| United Therapeutics Corporation | 2 | $45 |
| UCB, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Gilead | 2 | $30 |
| Baxter Healthcare | 1 | $29 |
| Melinta Therapeutics, LLC | 2 | $28 |
| Philips North America LLC | 1 | $25 |
| Harmony Biosciences LLC | 1 | $21 |
| Novartis | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Amgen | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,643
How this compares
$7,447 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $61,990 |
| NucalaMepolizumab | 12 | $44,356 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $27,050 |
| Spiriva RespimatTiotropium Bromide | 21 | $13,470 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,717 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $7,189 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,048 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $3,592 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,470 |
| Azithromycin | 19 | $649 |
| Montelukast Sodium | 18 | $380 |
| Pantoprazole Sodium | 15 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $444 | $111,39376 claims |
| AstraZenecaBreztri Aerosphere | $1,215 | $27,05037 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $630 | $22,18738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Lansing
- Miki YokokawaLansing$84K
- Robert GumbitaLansing$63K
- Khader HerzallahLansing$54K
- Christopher AlvaradoLansing$35K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.